Noah AI Industry News

Delivers real-time biopharma news and signals — powered by AI, curated for professionals.

ATyr Pharma's Efzofitimod Fails to Meet Primary Endpoint in Pulmonary Sarcoidosis Trial

ATyr Pharma's Efzofitimod Fails to Meet Primary Endpoint in Pulmonary Sarcoidosis Trial

ATyr Pharma, a biotechnology company focused on developing novel therapeutics, faced a significant setback as its lead drug candidate, efzofitimod, failed to meet its primary endpoint in a Phase 3 clinical trial for pulmonary sarcoidosis. The news, announced on September 15, 2025, sent shockwaves through the pharmaceutical industry and resulted in a dramatic plunge in the company's stock price.

NoahAI News9/16/2025
HHS Adds Five New Members to CDC Vaccine Advisory Panel Amid Ongoing Controversy

HHS Adds Five New Members to CDC Vaccine Advisory Panel Amid Ongoing Controversy

The Department of Health and Human Services (HHS) has appointed five new members to the Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP), continuing the overhaul initiated by HHS Secretary Robert F. Kennedy Jr. earlier this summer. This development comes ahead of a crucial ACIP meeting scheduled for later this week, where the panel will discuss and vote on recommendations for several vaccines, including those for COVID-19, hepatitis B, and measles, mumps, and rubella (MMR).

NoahAI News9/16/2025
FDA Approves Corstasis' Nasal Spray Diuretic, Enbumyst, for Edema Treatment

FDA Approves Corstasis' Nasal Spray Diuretic, Enbumyst, for Edema Treatment

The U.S. Food and Drug Administration (FDA) has granted approval to Corstasis Therapeutics' Enbumyst, a novel nasal spray formulation of the potent diuretic bumetanide. This landmark decision marks a significant advancement in the treatment of edema associated with congestive heart failure (CHF), chronic kidney disease (CKD), and liver disease.

NoahAI News9/16/2025
Flagship's Lila Sciences Secures $235M Series A to Expand AI-Driven Drug Discovery

Flagship's Lila Sciences Secures $235M Series A to Expand AI-Driven Drug Discovery

Lila Sciences, a Flagship Pioneering company, has announced a substantial $235 million Series A funding round, aimed at accelerating the development and expansion of its AI-powered autonomous research laboratories. This investment marks a significant milestone in the company's mission to revolutionize the drug discovery process through advanced automation and artificial intelligence.

NoahAI News9/16/2025
Novartis Expands Protein Degradation Partnership with Monte Rosa in $5.7B Deal

Novartis Expands Protein Degradation Partnership with Monte Rosa in $5.7B Deal

Novartis has significantly broadened its investment in protein degradation technology, announcing a second collaboration agreement with Boston-based Monte Rosa Therapeutics. The deal, potentially worth up to $5.7 billion, underscores the pharmaceutical giant's commitment to advancing targeted protein degradation as a promising approach for addressing immune-mediated diseases with high unmet needs.

NoahAI News9/15/2025
AstraZeneca Pauses UK Expansion as Pharma Giants Reconsider British Investments

AstraZeneca Pauses UK Expansion as Pharma Giants Reconsider British Investments

In a week marked by significant pullbacks from the UK pharmaceutical sector, AstraZeneca has become the latest industry titan to halt its expansion plans in Britain. The company has confirmed the suspension of a £200 million ($271 million) investment intended to bolster its research campus in Cambridge, adding to a growing list of setbacks for the UK's life sciences industry.

NoahAI News9/15/2025
CatalYm Overhauls Leadership Team to Accelerate Late-Stage Development of Cancer Immunotherapy

CatalYm Overhauls Leadership Team to Accelerate Late-Stage Development of Cancer Immunotherapy

German biotech firm CatalYm has announced a significant restructuring of its executive team, bringing in four industry veterans while bidding farewell to three long-standing leaders. The move is aimed at expediting the late-stage development of the company's promising cancer immunotherapy candidate, visugromab.

NoahAI News9/15/2025
Bristol Myers Squibb Divests Controlling Stake in Historic China Joint Venture

Bristol Myers Squibb Divests Controlling Stake in Historic China Joint Venture

Bristol Myers Squibb (BMS) has announced the sale of its controlling stake in Sino-American Shanghai Squibb Pharmaceuticals (SASS), marking a significant shift in the company's long-standing presence in China. This move comes more than four decades after BMS established the first U.S. pharmaceutical joint venture in the country.

NoahAI News9/15/2025
aTyr's Efzofitimod Fails to Meet Primary Endpoint in Phase 3 Pulmonary Sarcoidosis Trial

aTyr's Efzofitimod Fails to Meet Primary Endpoint in Phase 3 Pulmonary Sarcoidosis Trial

aTyr Pharma's phase 3 trial of efzofitimod for the treatment of moderate-to-severe pulmonary sarcoidosis has failed to meet its primary endpoint, dealing a significant blow to the company's prospects in the multibillion-dollar inflammatory lung disease market. Despite the setback, aTyr remains optimistic and plans to engage in discussions with the FDA regarding potential paths forward.

NoahAI News9/15/2025
B. Braun Acquires True Digital Surgery, Advancing Surgical Microscopy Technology

B. Braun Acquires True Digital Surgery, Advancing Surgical Microscopy Technology

B. Braun, a leading medical technology company, has announced the acquisition of True Digital Surgery (TDS), a specialist in digital, robotic-assisted 3D surgical microscopy. This strategic move aims to strengthen B. Braun's position in the rapidly evolving high-end microsurgery market, particularly in neurosurgery, spine, and ear, nose, and throat procedures.

NoahAI News9/15/2025
AI and Data Integration Drive Clinical Trial Diversity and Efficiency

AI and Data Integration Drive Clinical Trial Diversity and Efficiency

In a significant leap forward for the pharmaceutical industry, artificial intelligence (AI) and advanced data integration technologies are revolutionizing clinical trial recruitment and management. These innovations promise to address long-standing challenges in patient diversity and trial efficiency, potentially accelerating drug development while ensuring broader representation in medical research.

NoahAI News9/15/2025
Rosnilimab Shows Promise as Next-Generation Rheumatoid Arthritis Therapy in Phase 2b Trial

Rosnilimab Shows Promise as Next-Generation Rheumatoid Arthritis Therapy in Phase 2b Trial

A novel T cell-depleting therapy, rosnilimab, has demonstrated significant potential as a treatment for moderate-to-severe rheumatoid arthritis (RA) in a recent Phase 2b clinical trial. Developed by AnaptysBio, this investigational drug offers a unique approach to managing RA by selectively targeting pathogenic T cells, potentially addressing an unmet need in a market valued at over $20 billion in the United States alone.

NoahAI News9/15/2025
1234...67»